AM Edition: Here are the top 10 politics articles on LiveNews.co.nz for November 18, 2026 – Full Text
1. Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored
November 18, 2026
Source: Media Outreach
- Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies.
- Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery.
- Titia große Broermann: ” this year’s laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives”
WIESBADEN, GERMANY – Newsaktuell – 17 November 2026 – Prof. Svetlana Mojsov (The Rockefeller University), Prof. Dr. Richard DiMarchi (Indiana University), and Prof. Dr. Dr. h.c. Matthias H. Tschöp (Ludwig-Maximilians-Universität München) have been awarded the Broermann Medical Innovation Award 2026. Hessian Minister-President Boris Rhein presented the award during a ceremony at the Hessian State Chancellery.
Endowed with a total of one million euros, the Broermann Medical Innovation Award ranks among the world´s highest-endowed medical honors. This year, it honors three scientists whose fundamental work contributed decisively to enabling modern GLP-1-based therapies against obesity and diabetes. The award was endowed by Dr. Bernard große Broermann, founder of the Asklepios Kliniken Group.
In the presence of representatives from science, politics, and society, Minister-President Boris Rhein praised the international significance of the honored research achievements:
Boris Rhein, Minister-President of Hesse: “Through their research, Prof. Dr. Richard D. DiMarchi, Prof. Dr. Svetlana Mojsov, and Prof. Dr. med. Dr. h.c. Matthias Tschöp have opened a new chapter in metabolic therapy. Their work laid the scientific foundation for what is colloquially known as the “weight-loss injection.” From fundamental insights into human metabolism, a new generation of therapies has emerged, paving the way for effective treatments for diabetes and obesity, while also helping to manage or reduce associated secondary conditions.”
Prof. Dr. Werner Seeger, Chairman of the Jury for the Broermann Award, emphasized: “The work of this year’s laureates powerfully proves how scientific pioneering transforms into medical reality. Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide.”
Prof. Svetlana Mojsov stated: “I am humbled and honored to receive the Broermann Award for my work on GLP-1 that began over 40 years ago with a hypothesis and has gone to benefit the health and lives of millions of people worldwide.”
Prof. Dr. Richard DiMarchi noted: ” In the last decade, based upon a half century of research we have progressed with incretin-based medicines to transform the management of excess body weight analogous to historical treatment of excess glucose, cholesterol, and blood pressure. It is providing a transformative advance in public health and patient well-being.”
Prof. Dr. Dr. h.c. Matthias H. Tschöp added: “It is a great honor to receive this recognition together with Svetlana Mojsov and Richard DiMarchi. We are delighted that our decades of work on the scientific foundation and invention of therapeutic principles that ignited the modern obesity-drug revolution is receiving international recognition. It is especially rewarding to see how these discoveries are transforming the therapeutic landscape of diabetes, cardiovascular disease, fatty liver disease, and many other obesity-related conditions worldwide.”
Titia Olivia große Broermann, Shareholder of the Asklepios Kliniken Group, added: “The Broermann Medical Innovation Award stands for the conviction that medical progress begins where scientific courage meets the determination to sustainably improve patients’ lives. This year’s awardees impressively demonstrate how scientific curiosity and decades of research can give rise to therapies that transform the lives of millions of people. With this award, we aim to make their outstanding achievements visible while encouraging researchers worldwide to forge new paths. On behalf of my family and the Asklepios Kliniken Group, I congratulate Prof. Mojsov, Prof. DiMarchi, and Prof. Tschöp from the bottom of my heart.”
Foundations for a New Generation of Therapies
Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp were honord for their fundamental contributions to metabolic science. Their work on elucidating bioactive GLP-1, signal transmission between the gut and brain, and the development of multi-hormone co-agonists (polyagonists) laid the foundation for modern drugs for weight regulation and blood sugar control.
About the Award Winners
Prof. Svetlana Mojsov (born in Skopje, North Macedonia) earned her PhD in biochemistry at The Rockefeller University under Nobel laureate Bruce Merrifield, focusing on solid-phase peptide synthesis. During her research at Massachusetts General Hospital and Harvard Medical School in the 1980s, she identified and chemically synthesized the active 31-amino-acid form of Glucagon-Like Peptide-1 (GLP-1) and demonstrated its physiological role in stimulating insulin secretion. Her groundbreaking discoveries proved vital for the later development of GLP-1 receptor agonists. She currently serves as a Research Professor at The Rockefeller University in New York.
Prof. Dr. Richard DiMarchi (born in New York, USA) earned his PhD in biochemistry at Indiana University. Following academic research at The Rockefeller University, he led major research and development divisions at Eli Lilly and Company for over two decades, where he played a pioneering role in shaping the development of human insulin and analogues (Humalog®) and rHGH (Humatrope®) As a world-renowned peptide chemist and innovator, he holds over 100 patents and has co-founded eight successful biotech companies. He is currently Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University.
Prof. Dr. Dr. h.c. Matthias H. Tschöp (born in Munich, Germany) completed his medical studies at Ludwig-Maximilians-Universität (LMU) München. Following clinical work in endocrinology and research at Eli Lilly, he established research laboratories at the University of Cincinnati and Helmholtz Munich. Tschöp discovered the key role of ghrelin as the hunger hormon and, in close collaboration with Richard DiMarchi, developed the concept of multi-hormone co-agonists (dual and triple gut hormone receptor agonists such as GLP-1/GIP and GLP-1/GIP/glucagon molecules). He currently serves as President of LMU Munich.
About the Broermann Medical Innovation Award
The Broermann Medical Innovation Award was established in 2024 by Dr. Bernard große Broermann, namesake and founder of Asklepios Kliniken. Throughout his lifetime, Dr. große Broermann was distinguished by his vision of creating an innovative healthcare company that delivers genuine benefits to people. Under his leadership, Asklepios set standards in medical innovation, targeted investments in state-of-the-art medical technology and digital solutions, and thereby advanced patient care—values that also
form the foundation of the Broermann Medical Innovation Award. Through this award, his vision lives on and underscores a commitment that endures beyond his lifetime through his foundation.
2027 Nomination Phase
The nomination phase for the Broermann Medical Innovation Award 2027 has begun. Scientists from around the world can be nominated until March 1, 2027. Further information on the award, nomination criteria, and the selection process is available on the Award-Website
High-resolution photos of the award ceremony will be available for download shortly after the event at the following website: https://www.broermann-award.org/press/
– Published and distributed with permission of Media-Outreach.com.
Back to index · Read original article
2. Over 360 electricity distribution professionals meet in Seoul for CIRED’s first major event in the Asia-Pacific region
November 18, 2026
HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – CIRED’s first major event in the Asia-Pacific region took place on 2-3 November in Seoul, on the theme of digital disruption – AI and the next generation of distribution grids.
The workshop brought together more than 360 participants from 30 countries to exchange new research and ideas around the application of AI in power grid operation, grid planning and forecasting, and innovative business models, flexumer interaction and data governance.
Source: Media Outreach
Make Media OutReach Newswire your preferred source on Google
HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – CIRED’s first major event in the Asia-Pacific region took place on 2-3 November in Seoul, on the theme of digital disruption – AI and the next generation of distribution grids.
The workshop brought together more than 360 participants from 30 countries to exchange new research and ideas around the application of AI in power grid operation, grid planning and forecasting, and innovative business models, flexumer interaction and data governance.
Delegates learned from over 160 technical presentations, including CIRED’s trademark interactive poster tours. Three distinguished keynote speakers opened the first day: Jong-Bae Park, President of The Korean Institute of Electrical Engineers (KIEE); HaJoong Chung, Managing Director and Country Head, Siemens Korea, and Dr. Ja-Kyun Koo, Chairman & CEO, LS ELECTRIC Co., Ltd.
Expert round table sessions considered the value of flexibility in distribution network planning and operation, and real-world cases of AI applications in distribution network.
Alongside the conference sessions, attendees participated in a “Korean Night” gala dinner, technical site visits to Kepco Academy, and the Distribution Control Center (DCC) and Electricity Museum in Gangnam, as well as networking events that included a welcome reception and early morning sightseeing walk. Post-conference, there was also the chance to attend another major energy industry event: the BIXPO exhibition.
The CIRED Korean National Committee, who were the local organisers of the workshop, said:
“Hosting the CIRED Workshop in Seoul was a valuable opportunity to share Korea’s experience in distribution network operation and learn from colleagues around the world. The exchanges on AI, advanced distribution management and flexibility brought fresh perspectives to the challenges we share. We look forward to building on these connections through continued international cooperation to advance more reliable, flexible and sustainable distribution grids.”
The CIRED 2026 Seoul Workshop was sponsored by HD Hyundai Electric, Kepco, Kepco KDN, and LS Electric. It was supported by the Korea Tourism Organisation, Seoul Metropolitan Government, and Seoul BLeisure.
Hashtag: #CIRED #IET
About CIRED
‘CIRED’ is derived from Congrès International des Réseaux Electriques de Distribution, in English “International Conference on Electricity Distribution”. International conferences have been organised since 1971 by the Institution of Engineering and Technology (IET) and Association des Ingénieurs de Montefiore (AIM).
In April 2021, CIRED transformed into an international not-for-profit association, reflecting its ambition to expand its geographical coverage and not-for-profit mission.
For more information, visit https://www.cired.net/
Follow CIRED on LinkedIn: https://www.linkedin.com/company/cired-conference/
The issuer is solely responsible for the content of this announcement.
– Published and distributed with permission of Media-Outreach.com.
Back to index · Read original article
3. Disney and Visa Announce Multi-Year Strategic Alliance Across Asia Pacific
November 17, 2026
The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the region
HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney Company and Visa announced a multi-year strategic alliance across key Asia Pacific markets, establishing a long-term framework for the companies to collaborate on consumer experiences, co-branded payment programmes and joint marketing initiatives.
The Walt Disney Company and Visa celebrated their collaboration at Hong Kong Disneyland Resort, bringing together representatives from both companies and beloved Disney friends for a special moment at the resort.
Source: Media Outreach
Make Media OutReach Newswire your preferred source on Google
The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the region
HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney Company and Visa announced a multi-year strategic alliance across key Asia Pacific markets, establishing a long-term framework for the companies to collaborate on consumer experiences, co-branded payment programmes and joint marketing initiatives.
The Walt Disney Company and Visa celebrated their collaboration at Hong Kong Disneyland Resort, bringing together representatives from both companies and beloved Disney friends for a special moment at the resort.
The collaboration will introduce new ways for Disney fans and Visa customers to access Disney experiences across the region. Visa will serve as Disney’s exclusive payment network partner for Visa co-branded card programmes across key Asia Pacific markets. As part of the alliance, Visa will also serve as the Presenting Sponsor for the upcoming D23 Asia: The Ultimate Disney Fan Event, taking place June 25-27, 2027 in Singapore.
Eligible Visa cardholders can also look forward to exclusive perks and presale access to D23 Asia: The Ultimate Disney Fan Event, as well as special opportunities to experience Marvel Studios’ Avengers: Doomsday ahead of its theatrical release in select markets. At Hong Kong Disneyland Resort, planned privileges specifically for eligible Visa cardholders include early park entry, priority access to select entertainment offerings and dedicated character meeting experiences.
Additional experiences at Hong Kong Disneyland Resort and Shanghai Disney Resort may be introduced over time. The collaboration builds on Disney and Visa’s longstanding relationship in the United States and EMEA.
“This multi-year collaboration builds on our relationship with Visa and creates new ways for fans across Asia Pacific to connect with Disney,” said Ivan Lee, Vice President for Corporate Alliances, The Walt Disney Company Asia Pacific. “From Disney-branded Visa cards to special access and experiences, we look forward to bringing Disney’s unparalleled stories, experiences and products to consumers through a single, integrated alliance across the region.”
The collaboration reflects both companies’ commitment to delivering meaningful consumer experiences while creating new opportunities to engage audiences across one of the world’s most dynamic and fastest-growing regions.
Further details on benefits, cardholder eligibility, participating markets and launch timing will be announced in the coming months.
Hashtag: #HKDisneyland
About TWDC
About Visa
The issuer is solely responsible for the content of this announcement.
– Published and distributed with permission of Media-Outreach.com.
Back to index · Read original article
